Revisiting the Pharmaceutical Supply Chain: 2013-2018

JANUARY 2020

PREPARED BY:

Aaron Vandervelde
avandervelde@thinkbgr.com
202.480.2661

Andrew Brownlee
abrownlee@thinkbgr.com
202.747.3486
Executive Summary

In 2017, BRG professionals published a white paper studying the flow of dollars in the US pharmaceutical marketplace and how total spending on brand medicines at the point of sale is distributed across stakeholders that make up the US pharmaceutical supply chain.1 Since publication of that study, spending on prescription medicines in the US has continued to grow, and many of the market dynamics in place during the period of the original study (2013 through 2015) have persisted from 2016 through 2018. In this update to our original study, we seek to better understand which trends have continued, which new trends have emerged, and how the distribution of total point of sale brand medicine spending across the supply chain has evolved over the last three years.

For purposes of this paper, we narrow our focus to total spending on brand medicines, which we define as the sum of payments for brand medicines made by patients and their health plans at the point of sale (e.g., the pharmacy, outpatient hospital) prior to any rebate, discount, or fee provided by manufacturers. By using this starting point, the analysis makes it possible to measure prescription drug spending by consumers, health plans, government payers, and employers, and the portion thereof realized by manufacturer and non-manufacturer stakeholders. Key findings from our analysis include:

- Supply chain and other entities, including pharmacy benefit managers (PBMs), hospitals, pharmacies, and payers, now retain nearly half of all spending on brand medicines at the point of sale, while the biopharmaceutical companies that researched, developed, and manufactured the medicines retain 54%.

- The share of total brand medicine spending retained by biopharmaceutical manufacturers continues to decline. Manufacturers’ share of total brand medicine spending fell by 12.5 percentage points from 2013 to 2018.

- The increase in manufacturers’ total revenue from sales of brand medicines was in line with inflation between 2015 and 2018.

- 340B margins were nine times greater in 2018 than in 2013 and now account for almost two-thirds of total spending on brand medicines retained by providers (pharmacies and health care providers).

Key Findings

A common misconception of the pharmaceutical industry is that manufacturers retain the vast majority of drug spending. In our original study, we found that manufacturers’ share of total brand medicine spending was declining and represented 62.5% of the total in 2015. This trend accelerated over the last three years, and in 2018 manufacturers retained just 54.3%—down 12.5 percentage points from 66.8% in 2013 (see Figure 1). Despite absolute growth in brand medicine spending at the point of sale, which increased from $354 billion in 2015 to $440 billion in 2018, growth in the amount retained by manufacturers remained in line with inflation over the same period. Instead, supply chain and other entities are retaining an increasingly larger share of total brand medicine spending: 45.7% in 2018, up from 33.2% in 2013 (see Figure 1).

---

FIGURE 1
Percentage of Total Point of Sale Brand Medicine Spending Retained by Manufacturers and Other Entities, 2013-2018

Although total brand medicine spending at the point of sale increased from $269B in 2013 to $440B in 2018, the share of spending retained by manufacturers declined by 12.5 percentage points.

To better understand this dynamic, we studied changes in the share of total brand medicine spending retained by entities other than the manufacturers who research and developed the medicines. In each year from 2015 to 2018, payers (including health plans, PBMs, federal and state governments, and employer groups) received the largest share of the increase in total spending on brand medicines at the point of sale. From 2015 to 2018, payers received half of the increase (see Figure 2). This reflects the ability of payers to extract significant discounts and rebates off of the list price for brand medicines by leveraging increased competition in many therapeutic categories. This rebate growth is well documented, and the most recent Medicare Trustees Report found that rebates to Part D plans on brand medicines in 2018 represent a 25.3% discount off of the reimbursement amount, up from 12.9% in 2013.24

Although rebates lower the total cost of brand medicines to payers and keep net prescription drug price growth at very low levels (0.3% in 2018 for brand medicines), patients with coinsurance or deductibles often do not benefit directly from these rebates in the form of lower cost sharing at the point of sale.

FIGURE 2

Payers received the largest share of the increase in total point of sale brand drug spending between 2015 to 2018.

*Other includes wholesaler margin, patient cost sharing assistance, excise fees, and GPO administrative fees

*Payers include health plans, PBMs, the federal and state governments, and employer groups

---


3 The Medicare Trustees Report figure represents rebates received by Part D plans as a percentage of total Part D drug reimbursement. For purposes of this study, we accounted for the percentage of rebates withheld by PBMs in calculating rebates paid by manufacturers.

Providers—including pharmacies that dispense brand medicines to patients, as well as physicians and hospitals that administer brand medicines directly to patients—have also benefited from growth in total brand medicine spending. Provider margins accounted for $48.6 billion in total brand medicine spending in 2018, up from $24.7 billion in 2013 (see Figure 3). Unprecedented expansion in the 340B drug discount program during this period, including rapid adoption of 340B contract pharmacy networks, was the primary driver of this growth. Between 2013 and 2018, over 14,700 new pharmacies established contract pharmacy relationships with 340B covered entities; at the same time, over 9,500 covered entities registered in the 340B program for the first time. As a result of this growth, total margin on 340B purchased brand drugs was nine times greater in 2018 than 2013. Numerous for-profit contract pharmacies, along with the 340B covered entities with which they contract, benefited from this trend.

**FIGURE 3**
Gross Pharmacy and Provider Margin ($B)

Conclusions

Much attention is paid to topline growth in pharmaceutical spending, but manufacturers have not been the primary recipients of increasing total brand medicine spending over the past three years. Instead, other stakeholders in the pharmaceutical supply chain—payers and providers in particular—have benefited substantially from increased competition and expansion of the 340B program. Despite growing recognition of the market dynamics that underpin these trends, little has changed in how the pharmaceutical supply chain is structured or with the incentives that exist among supply chain participants. We anticipate that, absent new legislation or regulation to reform these aspects of the pharmaceutical supply chain, these trends will continue for the foreseeable future.

---

5 BRG analysis of Office of Pharmacy Affairs 340B covered entity and contract pharmacy databases
Defined Terms

**Brand Medicine:**
Innovator medicine with no marketed generic equivalent. The manufacturer typically negotiates rebates and discounts with payers for formulary placement and other forms of market access for retail drugs, and negotiates purchase discounts with providers for market access for non-retail drugs. Branded medicine drugs do not include any branded generic products.

**Rebates:**
Statutory and negotiated discounts that manufacturers pay to payers, including commercial and Part D rebates and administrative fees paid to payers, Medicaid rebates, TriCare rebates, and Federal Supply Schedule discounts.

**Total Brand Medicine Spending:**
Initial point-of-sale payment by a payer and patient for a brand medicine before accounting for negotiated rebates, discounts, or fees. Does not include dispensing fees or claims administration fees.
Appendix 1 – Methodology and Data Sources Considered

In preparing this update to our original study, we relied almost exclusively on the methodology used in the original study. The original publication includes a detailed methodology section, which can be referenced here. In certain instances, we elected to update our methodology to reflect new information gathered over the prior two years or to address deficiencies in data available to us. Additional information on these methodological updates is provided below.

**New Data Sources**

- IQVIA’s 2018 *Medicine Use and Spending in the US* report includes a detailed breakdown of manufacturer patient assistance for commercially insured patients. We utilized these figures to update the patient cost-sharing assistance portion of the share of total brand medicine spending.

- A recent publication by Milliman includes an estimate of commercial reimbursement for physician administered drugs as a percentage increase to Average Sales Price (ASP). We updated our original methodology to reflect the findings from this study.

**Methodological Update**

- We made a methodological update to the 340B margin for pharmacies and providers. Reimbursement for 340B purchases can be calculated by using the total purchases at the 340B price and the average 340B discount. We used the average Medicaid rebate percentage as a conservative estimate of the average 340B discount percentage.

**Total Brand Medicine Spending**

- “Total Brand Medicine Spending” represents the amount paid for a brand medicine at the point-of-sale, and does not account for negotiated rebates, discounts, fees, or other price concessions. Dispensing fees and/or claims administration fees are not included.

<table>
<thead>
<tr>
<th>Category</th>
<th>Component</th>
<th>Updated Source</th>
</tr>
</thead>
</table>

---

6 IQVIA (2019).
Appendix 2 – Total Point of Sale Payments for Brand Medicines by Component

<table>
<thead>
<tr>
<th>Total Point of Sale Payments for Brand Medicines by Component (in $billions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Component Type</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Statutory Rebates and Fees</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Market Access Rebates and Discounts</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Wholesaler and Provider Margins</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Total Point of Sale Payments for Brand Medicines</td>
</tr>
<tr>
<td>Net Amount Realized by Brand Manufacturer ($)</td>
</tr>
<tr>
<td>Net Amount Realized by Brand Manufacturer [%]</td>
</tr>
</tbody>
</table>

7 340B margin is included in the pharmacy and provider margin
About Berkeley Research Group

BRG is a global consulting firm that helps leading organizations advance in three key areas: disputes and investigations, corporate finance, and strategy and operations. Headquartered in California with offices around the world, we are an integrated group of experts, industry leaders, academics, data scientists, and professionals working beyond borders and disciplines. We harness our collective expertise to deliver the inspired insights and practical strategies our clients need to stay ahead of what’s next. Visit thinkbrg.com for more information.

About the Authors

AARON VANDERVELDE
avandervelde@thinkbrg.com | 202.480.2661
Aaron VanderVelde has over fifteen years of experience providing strategy, health policy, and litigation consulting services to clients in the healthcare industry. He specializes in financial and economic analysis of health policy and provides litigation consulting services related to issues arising from contracts and transactions between healthcare entities and with the federal government. Specifically, he focuses on deriving strategic insight through the integration and analysis of large, complex data sets including claims data, risk adjustment data, internal and external sales data, and publicly available health data.

ANDREW BROWNLEE
abrownlee@thinkbrg.com | 202.747.3486
Andrew Brownlee is a managing consultant in BRG’s Health Analytics practice. He uses his data analytics background to help understand, navigate, and solve complex issues in today’s healthcare environment. He provides advisory and litigation consulting services to entities across the healthcare spectrum by combining industry expertise with proprietary, client, and third-party data. He focuses on pharmaceutical forecasting, transactions, and compliance.